Acute Myeloid (RAM) Application

SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

Philippe Menu, M.D., PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. "We are proud to contribute to the fight against AML through our SOPHiA DDMâ„¢ RAM Solution. In particular we feel that the capability to seamlessly track longitudinally the evolution of individual mutations over time through a dedicated add-on module of our SOPHiA DDMâ„¢ Platform has the potential to be a game-changer for clinical researchers."